News & Updates

Fracture risk not higher with SGLT2 vs DPP4 inhibitors
Fracture risk not higher with SGLT2 vs DPP4 inhibitors
19 Feb 2023

The use of sodium-glucose transporter 2 (SGLT2) inhibitors among patients with diabetes does not pose an increased risk of developing fractures as compared with dipeptidyl-peptidase 4 (DPP4) inhibitors, and this is true across estimated glomerular filtration rate (eGFR) and albuminuria categories, as shown in a study.

Fracture risk not higher with SGLT2 vs DPP4 inhibitors
19 Feb 2023
Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
18 Feb 2023

Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.

Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
18 Feb 2023
Rising cases of community-acquired E. coli UTI in children a cause for concern
Rising cases of community-acquired E. coli UTI in children a cause for concern
18 Feb 2023

A recent study has found an increasing prevalence of community-acquired (CA) urinary tract infection (UTI) by emerging spectrum-β-lactamase-producing (ESBL) E. coli in children, with most isolates showing resistance to multiple drugs.

Rising cases of community-acquired E. coli UTI in children a cause for concern
18 Feb 2023
Endometrioma ups risk of failing antibiotic treatment for pelvic inflammatory disease
Endometrioma ups risk of failing antibiotic treatment for pelvic inflammatory disease
18 Feb 2023

Among women with pelvic inflammatory disease, the presence of endometrioma is associated with a lower likelihood of responding to antibiotic treatment and a higher risk of surgical intervention, according to a study.

Endometrioma ups risk of failing antibiotic treatment for pelvic inflammatory disease
18 Feb 2023